Business Services
Retail
Biopharmaceutical

Caladrius Biosciences

$3.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.33%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CLBS and other stocks, options, ETFs, and crypto commission-free!

About

Caladrius Biosciences, Inc. Common Stock, also called Caladrius Biosciences, is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Read More Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.

Employees
25
Headquarters
Basking Ridge, New Jersey
Founded
1980
Market Cap
31.15M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
108.25K
High Today
$3.02
Low Today
$2.95
Open Price
$3.02
Volume
1.46K
52 Week High
$11.65
52 Week Low
$2.77

Collections

Business Services
Retail
Biopharmaceutical
Pharmaceutical
Health
2015 IPO
US
North America

News

Yahoo FinanceMay 24

Edited Transcript of CLBS earnings conference call or presentation 9-May-19 8:30pm GMT

Q1 2019 Caladrius Biosciences Inc Earnings Call New York May 24, 2019 (Thomson StreetEvents) -- Edited Transcript of Caladrius Biosciences Inc earnings conference call or presentation Thursday, May 9, 2019 at 8:30:00pm GMT TEXT version of Transcript Scroll to continue with content Ad ================================================================================ Corporate Participants ================================================================================ * David J. Mazzo Caladrius Bioscie...

0
Seeking AlphaMay 9

Caladrius Biosciences, Inc.'s CEO David Mazzo on Q1 2019 Earnings Conference Call Transcript

Caladrius Biosciences, Inc. (NASDAQ:CLBS) Q1 2019 Results Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants John Menditto - VP IR & Corporate Communications David Mazzo - President & CEO Joseph Talamo - SVP & CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright Steve Brozak - WBB Securities Jason Kolbert - Dawson James Securities Pete Enderlin - MAZ Partners Keay Nakae - Chardan Securities Operator Welcome to the Caladrius Biosciences First Quarter 2019 Financia...

20
Yahoo FinanceMay 9

Caladrius Biosciences Reports 2019 First Quarter Financial Results and Provides Corporate Update

All enrolling clinical programs advancing with top-line data expected in late 2019 and during 1H2020 for CLBS14-CMD and CLBS12, respectively CLBS14-NORDA phase 3 program targeted to begin enrollment in late 2019 Cash on hand projected to support existing programs through 2Q2020 Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., May 09, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceut...

12

Earnings

-$0.78
-$0.64
-$0.50
-$0.36
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.